Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Biofrontera ( (DE:B8FK) ).
Biofrontera AG has raised its EBITDA forecast for fiscal 2025, now expecting between EUR 3.5 million and EUR 5 million, up from a prior range of EUR 1.5 million to EUR 3.5 million, based on preliminary figures. The company is keeping its revenue outlook unchanged at EUR 17 million to EUR 20 million, signaling anticipated margin improvement and a potentially stronger operating performance without relying on higher sales.
The upgraded profit guidance suggests Biofrontera is benefiting from cost efficiencies or a more profitable sales mix, which could enhance its financial stability and attractiveness to investors. Maintaining the revenue forecast while lifting EBITDA expectations may also indicate management’s confidence in execution and operational leverage within its existing market footprint.
More about Biofrontera
Biofrontera AG is a Germany-based biopharmaceutical company listed on regulated markets in Düsseldorf and Frankfurt as well as several free markets in Germany. The company focuses on developing and commercializing dermatological therapies, with its revenue base concentrated in specialized pharmaceutical products for skin conditions.
Average Trading Volume: 1,321
Technical Sentiment Signal: Strong Sell
Current Market Cap: €14.77M
For an in-depth examination of B8FK stock, go to TipRanks’ Overview page.